AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06225622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
Study NCT06317103 — intervention group
Intervention type: DEVICE
Intervention: WADYMED endo
Description: Classification of the gastro-endoscopic images as Mucosa or Submucosa by WADYMED endo (Gastric cancer image, computer aided detection/diagnosis software)
Study NCT06317103 — intervention group
Intervention type: OTHER
Intervention: Control group (the endoscopists)
Description: Interpretation of the gastro-endoscopic images as Mucosa or Submucosa by the endoscopists
Study NCT06298344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Daily Thiamine 100 mg in 28 days
Study NCT04644367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Description: TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.
Study NCT04644367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Physical Activity (control) group
Description: Regular Physical Activity group who will not be receiving the TC intervention
Study NCT04929665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two different block and combination of these two blocks
Description: Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
Study NCT06409793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
Study NCT06409793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
Study NCT05463198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1600
Description: Subjects undergoing blood donation will be connected to the CM-1600 device.
Study NCT05538052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
Study NCT05538052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
Study NCT05538052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
Study NCT05068648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Wheelchair (MWC) backrest configuration
Description: Wheelchair backrest fitting, postural and functional assessment
Study NCT05062473 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Modification Webinars Focused on Hypertension Control
Description: Participation in a 12-week health education telemedicine curriculum
Study NCT05318326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Study NCT05318326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yogliptin 400mg group
Description: Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Study NCT05318326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yogliptin 200mg group
Description: Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Study NCT06348043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jarvik 2015 LVAD
Description: Medical device used to treat children awaiting heart transplant who fail optimal medical therapy.
Study NCT06376721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.
Study NCT06376721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.
Study NCT06376721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle.~Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
Study NCT06376721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
Study NCT05643664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prosthetics of the abdominal aorta
Description: aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.
Study NCT05643664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prosthetics of the abdominal aorta after determining the safe zones of clamping
Description: aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
Study NCT04747405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapy group
Description: therapy group of maximum 8 people repeated twice
Study NCT06444438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: subarachnoid hemorrhage
Description: CT presented subarachnoid hemorrhage
Study NCT06606028 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Specimen Collection
Description: Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point
Study NCT06606028 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Tissue Collection
Description: Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening
Study NCT06606028 — intervention group
Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care
Study NCT05710432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quasi-Isometric Neck Flexion
Description: Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
Study NCT05710432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued.
Study NCT06386328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378, QD, PO
Description: CKD-378, QD, PO
Study NCT04854330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone monoesters
Description: A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml.
Study NCT04854330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
Study NCT04680962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MabionCD20 (candidate biosimilar to rituximab)
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml
Study NCT05198648 — intervention group
Intervention type: OTHER
Intervention: Trigeminal cardiac reflex
Description: Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
Study NCT05198648 — intervention group
Intervention type: OTHER
Intervention: Non-trigeminal cardiac reflex
Description: No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
Study NCT06320444 — intervention group
Intervention type: PROCEDURE
Intervention: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
Description: Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task.~Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation.~These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)
Study NCT05444140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: The health coaching programme includes four monthly health coaching sessions for three months.
Study NCT05995444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epetraborole and matching placebo
Description: Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
Study NCT05995444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
Study NCT05995444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
Study NCT05995444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
Study NCT04659993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemental Health Sessions, Support Groups and Questionnaires
Description: Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
Study NCT04680962 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabionCD20 (candidate biosimilar to rituximab)
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml
Study NCT05217914 — intervention group
Intervention type: DRUG
Intervention: Copanlisib (BAY80-6946)
Description: Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
Study NCT04680962 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera®
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml
Study NCT04680962 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan®
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml
Study NCT04784962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive Medic Neuromuscular Stimulation Device
Description: Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).
Study NCT04784962 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Revitive Medic Neuromuscular Stimulation Device (Sham)
Description: Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
Study NCT06005584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation - High Frequency SCS
Description: High Frequency-SCS consists of delivering electrical stimulation at frequencies equal to or greater than 1kHz.~This intervention will last up to 6 weeks.
Study NCT06005584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation - Burst SCS
Description: Burst SCS consists of closely spaced, high frequency stimuli delivered to the spinal cord.~This intervention will last up to 6 weeks.
Study NCT06005584 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal Cord Stimulation - Sham SCS
Description: This intervention will last up to 6 weeks.
Study NCT05034640 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional multiport thoracoscopic surgery
Description: Use 2 or more incisions for multiple instrument entry during the surgery and chest tube placement at the end of the operation.
Study NCT05034640 — intervention group
Intervention type: PROCEDURE
Intervention: Single port site thoracoscopic surgery
Description: Using only 1 incision for multiple instrument entry during the surgery and chest tube placement at the end of the operation. Single port - GelPOINT Mini® port (Applied Medical, Rancho Santa Margarita, California, USA)
Study NCT05739773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: five-element music therapy
Description: music therapy
Study NCT05739773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: five-element music therapy
Description: music therapy
Study NCT06322758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume customization in the acute respiratory distress syndrome
Description: During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
Study NCT06322758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume customization in the acute respiratory distress syndrome
Description: During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
Study NCT04974788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Respiratory Muscle Training
Description: Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
Study NCT04974788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium Intensity Respiratory Muscle Training
Description: Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
Study NCT04974788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Respiratory Muscle Training
Description: Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Establishment of a hierarchical monitoring and management team
Description: To be specific, the head nurse served as the team leader to conduct comprehensive macro supervision; moreover, there were 3 responsible team leaders and 6 responsible nurses, all of whom had rich clinical nursing experience and solid theoretical knowledge of pressure injury. Consequently, a joint-action mechanism of the head nurse - responsible team leader - responsible nurses was developed to facilitate the unification of the training of nursing content, precautions, etc.
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of pressure injury
Description: Based on the postoperative coma of patients, the Braden assessment scale was applied to effectively evaluate patients from six dimensions of sensory perception, moisture, activity mode, mobility, nutrition, friction, and shear. The total score was 23 points. Patients scoring 13\~14 points were evaluated by Braden once per week; and those scoring ≤12 points were evaluated at a frequency of 3d/ time.
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication
Description: Through intensive face-to-face communication with family members, timely information on the surgical effect, mechanism of pressure injury, preventive measures, and clinical manifestations through intuitive methods such as PPT and video, family members were taught with basic knowledge of pressure injury, and guided to inform medical staff in a timely manner when patients had symptoms of pressure ulcer. Simultaneously, by case sharing and positive suggestions, family members were supported to alleviate their concerns and improve their coordination with treatment
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for pressure ulcer
Description: For patients with a Braden score of >14 points, attention should be paid to keeping skin dry and clean, regularly changing bed sheets and bedding (once per day). Patients with Braden score of 13-14 points should be provided with sponge mattresses, increased times of turning over once per 2 hours, and soft pillows or foam dressings at the site of occipital protuberance to relieve pressure and prevent pressure injury. For patients with Braden score ≤12 points, medical staff should repeatedly emphasize to their families the harm of pressure injury to postoperative recovery.
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation training
Description: After regaining consciousness with stable vital signs, patients received rehabilitation training following the principle of association of activity and inertia in a regular order. Patients were guided to perform upper limb movements, joint flexion, lower limb flexion and extension, as well as daily training such as washing face, rinsing mouth, and dressing at a frequency of 3\~4 times/d. Moreover, patients were advised to minimize violent behaviors such as laughing and talking loudly
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Description: After regaining consciousness with stable vital signs, patients received rehabilitation training following the principle of association of activity and inertia in a regular order. Patients were guided to perform upper limb movements, joint flexion, lower limb flexion and extension, as well as daily training such as washing face, rinsing mouth, and dressing at a frequency of 3\~4 times/d. Moreover, patients were advised to minimize violent behaviors such as laughing and talking loudly
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: introduction of the current patient's condition to family members
Description: timely introduction of the current patient's condition to family members to alleviate their concerns
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: maintaining appropriate temperature and humidity in the ward
Description: maintaining appropriate temperature (20 ℃\~22 ℃) and humidity (60.0%\~70.0%) in the ward
Study NCT06329934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: careful observation of vital signs in patients
Description: careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients